Advertisement
Microbot Medical Announces Positive Results For GLP Pivotal Pre-Clinical Study; Stock Up 15%
(RTTNews) - Microbot Medical Inc. (MBOT) announced Thursday the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model.
As previously announced on December 7, 2023, the study was conducted by three leading interventional radiologists that utilized the LIBERTY Endovascular Robotic Surgical System to perform a total of 96 robotic navigations.
The target vessels with surrounding tissue were examined and evaluated microscopically after they were subjected to procedures using a range of commercially available intravascular catheterization devices controlled and manipulated via the LIBERTY Endovascular Robotic Surgical System.
The company said it continues to transition from R&D and pre-clinical phase into the clinical, regulatory and pre-commercial phase. The company expects to submit its IDE application to the FDA soon and commence the pivotal human clinical trial.
Sensex, Nifty To Open On Sluggish Note As Investors Weigh Trump Tariffs
Thai Stock Market May See Continued Support On Thursday
Australia June Trade Surplus A$5.365 Billion
Australia Building Approvals Jump 11.9% In June
Japanese Market Notably Higher
Indonesia Shares Expected To Remain Rangebound On Thursday
Hong Kong Shares Tipped To Open To The Upside
